Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 10.
doi: 10.1111/hae.70143. Online ahead of print.

F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A

Ming Y Lim  1 , Kristy Lee  2 , Jill M Johnsen  3   4 , Nigel S Key  5
Affiliations

F8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A

Ming Y Lim et al. Haemophilia. .

Abstract

Background: Neutralising antibodies (inhibitors) against factor VIII can result in severe bleeding in persons with nonsevere haemophilia A (NSHA). The INSIGHT study of 1112 persons with NSHA in a predominantly White population identified 19 different F8 missense variants that were associated with inhibitor development.

Objective: To describe the F8 variants and inhibitor development in persons with NSHA in a multiethnic cohort using the My Life, Our Future (MLOF) Research Repository and the American Thrombosis and Hemostasis Network dataset (ATHNdataset).

Methods: The MLOF Research Repository and ATHNdataset were queried for demographic, clinical and genotyping data.

Results: A total of 1805 persons with NSHA with at least one reportable F8 variant and known inhibitor status were included in this study. Inhibitors were developed in 142 (7.9%) persons with NSHA. Inhibitor development occurred in seventy F8 variants, of which the majority (n = 67, 95.7%) were missense variants. These 70 F8 variants were identified in a total of 1006 (55.7%) persons with NSHA. Race or ethnicity was not associated with inhibitors in persons with NSHA.

Conclusion: The MLOF Research Repository identified additional F8 variants where inhibitor development occurred in a multiethnic cohort of NSHA. Identification of these F8 variants can inform both physicians and persons with NSHA to adopt measures to reduce the risk of inhibitor development.

Keywords: ethnicity; genotype; haemophilia A; racial groups; risk.

PubMed Disclaimer

References

    1. J. Wight and S. Paisley, “The Epidemiology of Inhibitors in Haemophilia A: A Systematic Review,” Haemophilia 9, no. 4 (2003): 418–435, https://doi.org/10.1046/j.1365‐2516.2003.00780.x.
    1. C. L. Eckhardt, A. S. van Velzen, M. Peters, et al., “Factor VIII gene (F8) Mutation and Risk of Inhibitor Development in Nonsevere Hemophilia A,” Blood 122, no. 11 (2013): 1954–1962, https://doi.org/10.1182/blood‐2013‐02‐483263.
    1. C. L. Eckhardt, J. I. Loomans, A. S. van Velzen, et al., “Inhibitor Development and Mortality in Non‐Severe Hemophilia A,” Journal of Thrombosis and Haemostasis 13, no. 7 (2015): 1217–1225, https://doi.org/10.1111/jth.12990.
    1. J. Boekhorst, G. R. Lari, and R. D'Oiron, “Factor VIII Genotype and Inhibitor Development in Patients With Haemophilia A: Highest Risk in Patients With Splice Site Mutations,” Haemophilia 14, no. 4 (2008): 729–735, https://doi.org/10.1111/j.1365‐2516.2008.01694.x.
    1. S. C. Gouw, H. M. van den Berg, J. Oldenburg, et al., “F8 Gene Mutation Type and Inhibitor Development in Patients With Severe Hemophilia A: Systematic Review and Meta‐Analysis,” Blood 119, no. 12 (2012): 2922–2934, https://doi.org/10.1182/blood‐2011‐09‐379453.

LinkOut - more resources